Patents by Inventor Donglei Liu

Donglei Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3-substituted cyclobutyl derivatives and uses thereof
    Patent number: 11845730
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Inventors: Donglei Liu, Julien Papillon, Stefan Peukert, James J. Powers
  • NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
    Publication number: 20230203032
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1 and R3 are as described herein, as well as compositions and methods of using such compounds.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Atwood Kim CHEUNG, Donglei LIU, Stefan PEUKERT, Heng GE, Yu GAI, Xingjuan CHANG
  • 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
    Publication number: 20220324811
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Application
    Filed: March 24, 2022
    Publication date: October 13, 2022
    Inventors: Donglei LIU, Julien PAPILLON, Stefan PEUKERT, James J. POWERS
  • Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9765067
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Takeru Ehara, Luciana Ferrara, Nan Ji, Donglei Liu, Erik Meredith, Muneto Mogi, James Powers, Ganesh Prasanna, Mitsunori Kato
  • THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197950
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Takeru EHARA, Luciana FERRARA, Nan JI, Donglei LIU, Erik MEREDITH, Muneto MOGI, James POWERS, Ganesh PRASANNA, Mitsunori KATO
  • Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
    Publication number: 20160145247
    Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: David B. BELANGER, Stefanie FLOHR, Christine Fang GELIN, Keith JENDZA, Nan JI, Donglei LIU, Edwige Lilliane Jeanne LORTHIOIS, Rakeshri Ganesh KARKI, Nello MAINOLFI, James J. POWERS, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI, Taeyoung YOON
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8541432
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 24, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8501756
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8492393
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 23, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8486954
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 16, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8431584
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: April 30, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130012529
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005753
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005751
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005750
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20120245187
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: June 5, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMANN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8242125
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Heterobicyclic Carboxamides as inhibitors for kinases
    Publication number: 20100168082
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: December 7, 2009
    Publication date: July 1, 2010
    Inventors: Gerald David Artmann, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions
    Publication number: 20070213339
    Abstract: Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.
    Type: Application
    Filed: March 31, 2005
    Publication date: September 13, 2007
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Uday Khire, Xiao-Gao Liu, Dhanapalan Nagarathnam, Jill Wood, Lei Wang, Donglei Liu, Jin Zhao, Leatte Guernon, Lei Zhang
  • 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
    Patent number: 7109196
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: September 19, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi